Last reviewed · How we verify
IPV at 14 and 22 weeks of age, RotaTeq — Competitive Intelligence Brief
marketed
Biologic
Live · refreshed every 30 min
Target snapshot
IPV at 14 and 22 weeks of age, RotaTeq (IPV at 14 and 22 weeks of age, RotaTeq) — Centers for Disease Control and Prevention.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| IPV at 14 and 22 weeks of age, RotaTeq TARGET | IPV at 14 and 22 weeks of age, RotaTeq | Centers for Disease Control and Prevention | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- IPV at 14 and 22 weeks of age, RotaTeq CI watch — RSS
- IPV at 14 and 22 weeks of age, RotaTeq CI watch — Atom
- IPV at 14 and 22 weeks of age, RotaTeq CI watch — JSON
- IPV at 14 and 22 weeks of age, RotaTeq alone — RSS
Cite this brief
Drug Landscape (2026). IPV at 14 and 22 weeks of age, RotaTeq — Competitive Intelligence Brief. https://druglandscape.com/ci/ipv-at-14-and-22-weeks-of-age-rotateq. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab